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 Coffin-Lowry syndrome (CLS) is an X-linked dominant 
syndrome characterized in males by severe intellectual dis-
ability, short stature, facial dysmorphism, peculiar hands 
(short, soft and fleshy), and progressive kyphoscoliosis 
[Lowry et al., 1971]. It is caused by highly heterogeneous 
loss-of-function mutations in the  RPS6KA3 gene located 
on Xp22.12 [Pereira et al., 2010]. Heterozygous females are 
less severely affected. About 20% of individuals with CLS 
present stimulus-induced drop episodes (SIDEs) which 
typically start from middle childhood to the teens [Ste-
phenson et al., 2005], and 5% of individuals are also re-
ported to be affected by epileptic seizures [Touraine et al., 
2002; Hahn and Hanauer, 2012]. To the best of our knowl-
edge, this is the first description of status epilepticus in 
CLS. We report on an adult patient presenting with recur-
rent episodes of nonconvulsive status epilepticus (NCSE).
 Clinical Report 
 The male patient was first admitted to hospital at the age of 
45 years because of a sudden episode of fluctuating decreased 
alertness; a second, very similar episode recurred one year later. 
He is an orphan living in an institution, and both his family and 
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 Abstract 
 Coffin-Lowry syndrome (CLS) is a rare neurodevelopmen-
tal condition caused by heterogeneous mutations in the 
 RPS6KA3 gene on the X chromosome, leading to severe in-
tellectual disability and dysmorphism in men, while women 
are carriers and only weakly affected. CLS is well known for 
stimulus-induced drop episodes; however, epilepsy is not 
commonly reported in this condition. We report on a CLS 
patient presenting with recurrent episodes of nonconvul-
sive status epilepticus (NCSE) with generalized epileptic ac-
tivity, for which investigations did not find any other cause 
than the patient’s genetic condition. This case underlines 
that the possibility of nonconvulsive epileptic seizures and 
status epilepticus should, therefore, be considered in those 
patients. The treatable diagnosis of NCSE may easily be 
overlooked, as symptoms can be unspecific. 
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past medical history are very poorly documented. Allegedly, he 
suffered from marked learning disabilities since early childhood. 
The first available medical records at the age of 37 years report 
severe mental handicap, but no other medical history. Upon ex-
amination, the patient presented with a happy and quiet demean-
or, was of short stature (158 cm), had a severe kyphoscoliosis, and 
had no verbal communication. He had dysmorphic features with 
coarse facial traits, slightly downslanting palpebral fissures, a 
short philtrum, a long tongue, hypodontia, and a thick everted 
lower lip. ( fig. 1 a). Postaxial polydactyly was noted on his left foot 
( fig. 1 b), and his fingers were neither particularly stubby nor ta-
pering, as often described in textbooks. For several years, the pa-
tient had been experiencing attacks of very sudden lower limb 
weakness, especially when he got surprised, making him fall 
down. He needed walking assistance because of an ataxic gait. He 
never experienced epileptic seizures previously. Both episodes 
presented with repeated losses of contact of  ∼ 30 s, occurring 20 
times over 2 h, with tonic head movement to the left, subtle hand 
myoclonus and purposeless arm movements, profuse sweating 
and salivation, and associated with urinary incontinence. At ad-
mission, he continued to experience episodes of head movements 
to the left with decreased awareness, as he underwent a video-
EEG ( fig. 2 a). The recording showed generalized continuous ictal 
activity (discharges of polyspikes) which resolved after adminis-
tration of 1 mg of intravenous clonazepam ( fig. 2 b). The patient 
was then loaded with 1,000 mg of levetiracetam (20 mg/kg intra-
venous). The work-up did not disclose any other known cause of 
status epilepticus. Brain MRI showed no major abnormality, but 
some minor unspecific punctiform T2-hyperintensities in the 
frontal white matter and moderately enlarged lateral ventricles 
(most notably on the posterior horns). The patient was dis-
charged on levetiracetam 750 mg per os daily. A year later, while 
the treatment of levetiracetam was continued at the same dosage, 
very similar episodes suddenly occurred again with varying in-
tensity. Upon admission to the hospital, he was administered an 
intravenous loading dose of 1,000 mg levetiracetam, which 
stopped the seizures. The patient recovered rapidly, and the fol-
lowing day, his EEG was devoid of epileptiform activity. Ictal le-
vetiracetam serum level upon admission was detectable at 32 
μmol/l, i.e. below the reference range, but in keeping with the 
relatively low dose he had been taking. Consequently, the dosage 
was increased to 1,250 mg daily. When the patient experienced 
another similar episode of NCSE while on monotherapy, and no 
triggering factor was identified for this second episode, the treat-
ment was intensified with the addition of another wide-spectrum 
antiepileptic drug (valproate 500 mg daily). After the second ep-
isode, the diagnosis of CLS was postulated upon review of the 
patient’s photographs. X-rays of the hands were performed and 
showed the typical tufted drumstick appearance of distal phalan-
ges ( fig. 1 c). Genetic analysis of the  RPS6KA3 gene confirmed the 
diagnosis.
a b
c
Fig. 1.  a The patient at the age of 45 years. 
Note the facial dysmorphisms with coarse 
facial traits, slightly downslanting palpe-
bral fissures, a long, folded tongue, and a 
thick everted lower lip.  b Postaxial poly-
dactyly of the patient’s left foot.  c X-rays of 
the patient’s hands showing the so-called 
tufting of all distal phalanges (circles).
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 Genetic Analysis 
 Molecular analysis of  RPS6KA3 (ribosomal protein S6 ki-
nase, 90kDa, polypeptide 3; OMIM 300075) showed a previous-
ly undescribed hemizygous mutation c.575G>C (p.R192T). Giv-
en the high degree of conservation of the mutated nucleotide 
and the type of amino acid change, it was considered that this 
variant was most likely the cause of the patient’s phenotype (to-
gether with the following prediction scores for clinical signifi-
cance: Mutation Taster: ‘disease causing’, probability = 1.0; 
PolyPhen-2: ‘probably damaging’, score: 1.000; SIFT: ‘tolerat-
ed’, score 0.19). Unfortunately, his mother had passed away in 
1971, and no maternal relatives were available to study the seg-
regation of this mutation.
 Discussion 
 Our patient was diagnosed with CLS very late in his 
life. Retrospective diagnoses of childhood conditions in 
adults living in institutions can be challenging at times 
because early medical records are rarely available and 
parents may have deceased. His clinical and X-ray fea-
tures were compatible with previous reports on CLS 
[O’Riordan et al., 2006; Wang et al., 2006], which prompt-
ed molecular genetic diagnosis. CLS is well known for 
paroxysmal SIDEs. Their pathophysiology is not clear so 
far. They have been termed cataplexy, hyperekplexia, 
a
b
 Fig. 2. EEG of the first episode (average 
montage).  a Ictal recording was marked by 
subcontinuous bursts of polyspikes and 
 intermingled diffuse spike waves (1–3 s) 
without clear temporal correlation with the 
head movements. Background activity was 
diffusely slow.  b After treatment, the re-
cording showed only slow low-voltage 
background activity. 
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nonepileptic collapses with atonia, or exaggerated startle 
responses [Havaligi et al., 2007]. Others have described 
them as cataplexy-like events, characterized by sudden 
quadriceps hypotonia with subsequent collapse, or hy-
perekplexia-like episodes, with a startle response to 
mostly auditory or tactile stimuli [Hahn and Hanauer, 
2012]. SIDEs are widely considered as nonepileptic epi-
sodes [Nelson and Hahn, 2003; Hahn and Hanauer, 
2012].
 Epileptic seizures in CLS are rarely reported. In large 
series, only 5% of patients with CLS were described to 
have epileptic seizures [Hunter, 2002; Stephenson et al., 
2005], while other authors question if this truly repre-
sents an increased prevalence, as the occurrence of epi-
lepsy is commonly reported in more than 5% of persons 
with mild learning disabilities and in up to 24% of per-
sons with severe learning disabilities [Steffenburg et al., 
1995; Lhatoo and Sander, 2001; Hahn and Hanauer, 
2012], compared to a prevalence of around 1% in the 
general population [Picot et al., 2008]. It is, however, 
commonly thought that in individuals with learning dis-
abilities, the increased prevalence of epilepsy is related to 
the fact that both epilepsy and learning disabilities are 
symptoms of a common underlying condition [Lhatoo 
and Sander, 2001]. In the specific case of CLS, mutations 
of  RPS6KA3 have wide implications [Sassone-Corsi et 
al., 1999] but without any direct link to known epilepto-
genic pathways [Ottman et al., 2010; Allen et al., 2013]. 
An association with epilepsy was however reported in a 
family with an Xp22.12 microduplication encompassing 
 RPS6KA3 [Matsumoto et al., 2013].  RPS6KA3 , expressed 
in the brain, although less markedly in the cortex (www.
genecards.org) [Rappaport et al., 2014], is the major gen-
erator of epileptic seizures. One of the pathways, modu-
lated by the gene, is NMDA receptor activation, a func-
tion conceivably involved in the occurrence of seizures 
[Moldrich et al., 2003].
 Our patient presented with recurrent unprovoked 
NCSE with an EEG showing a peculiar generalized pat-
tern (long runs of polyspikes), typically seen in symptom-
atic generalized epilepsies [Sutter and Kaplan, 2012], the 
etiology of which is increasingly demonstrated to be ge-
netic [Allen et al., 2013]. Although the short duration of 
the repeated clinical episodes may have suggested repeat-
ed absence seizures, we underline that recurrent motor 
manifestations suggestive of focal seizures as well as gen-
eralized continuous epileptic activity usually associated 
with tonic seizures make the best description of the pa-
tient as NCSE [Sutter and Kaplan, 2012], further high-
lighting the peculiarity of those episodes. Investigations 
did not disclose any alternative cause than the patient’s 
underlying genetic condition. The relatively unspecific 
semiology of these episodes and absence of convulsions 
may easily have been overlooked and misdiagnosed as be-
havioral changes, or as a nonspecific deterioration in the 
general state of health occurring in parallel to medical 
complications in a patient with severe learning disabili-
ties. This case highlights that prolonged nonconvulsive 
seizures and status epilepticus can occur in CLS. There-
fore, this possibility should be considered in those pa-
tients in cases of altered behavior or a decreased general 
state of health, even though seizures per se are not a fre-
quently reported feature of CLS.
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